Clinical Trials Logo

Filter by:
NCT ID: NCT02970786 Recruiting - Breast Cancer Clinical Trials

Phase I Trial: 68Ga-NODAGA-E(c[RGDyK])2 Positron Emission Tomography for Imaging Angiogenesis in Primary and Metastatic Tumor Lesions in Humans

Start date: November 2016
Phase: Phase 1
Study type: Interventional

The primary objective of the trial is to test the new radio tracer 68Ga-NODAGA-E[c(RGDyK)]2 for PET imaging of angiogenesis. The tracer has the potential of identifying tumors with a high level of angiogenesis, which is one of the cancer hallmarks. Furthermore, the tracer can potentially be used in early response assessment to anti-angiogenic treatment. This is a first-in-man study to test the radio tracer in cancer patients. Safety, biodistribution and dosimetry will be evaluated by repeated PET imaging (10 minutes, 1 hour and 2 hours post injection).

NCT ID: NCT02961647 Recruiting - Clinical trials for Mitral Valve Regurgitation

Hemodynamic Stress Test in Severe Mitral Regurgitation (HEMI)

HEMI
Start date: October 2014
Phase: N/A
Study type: Observational

The preferred treatment of organic mitral regurgitation (MR) is mitral valve repair. Optimally this should be timed so late that it commensurate with the risk of surgery and before irreversibly damage of the heart and pulmonary vessels. The aim is to obtain an understanding of the differences between the symptomatic and asymptomatic patient. The study will test A: Symptomatic organic MR is characterized by higher filling pressure, and higher stroke work during physical strain compared with asymptomatic MR. B: The extent of myocardial fibrosis is associated with filling pressure and cardiac index 1 year after mitral valve repair. C: Filling pressure can be estimated non-invasively by echocardiography. To test this 40 patients with asymptomatic MR and 40 symptomatic will undergo a stress echocardiography with simultaneous echocardiography and invasive measurement of central hemodynamics. In addition a pulmonary function test and cardiac MRI will be performed.

NCT ID: NCT02960724 Recruiting - Neoplasms Clinical Trials

uPAR PET/CT for Staging Advanced and Localised Oral and Oropharyngeal Cancer

Start date: November 2016
Phase: Phase 2
Study type: Interventional

uPAR PET/CT for Staging Advanced and Localised oral and oropharyngeal cancer

NCT ID: NCT02960022 Recruiting - Prostate Cancer Clinical Trials

A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Start date: December 22, 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to collect long term safety data in subjects who are continuing to derive clinical benefit from treatment with Enzalutamide from the subjects participation in an enzalutamide clinical study sponsored by Astellas or Medivation (i.e., parent study) which has completed, at a minimum, the primary analysis or the study specified evaluation period.

NCT ID: NCT02945826 Recruiting - Clinical trials for Glioblastoma Multiforme

uPAR-PET/MRI in Glioblastoma Multiforme

Start date: January 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study is to investigate the applicability of urokinase plasminogen activator receptor (uPAR) Positron Emission Tomography (PET) / MRI molecular imaging of glioblastoma.

NCT ID: NCT02945566 Recruiting - Clinical trials for Adenocarcinoma of the Rectum

Can we Save the Rectum by Watchful Waiting or TransAnal Surgery Following (Chemo)Radiotherapy Versus Total Mesorectal Excision for Early REctal Cancer?

STAR-TREC
Start date: June 14, 2017
Phase: Phase 2/Phase 3
Study type: Interventional

Bowel cancer is the second most common tumour with 41 000 new cases diagnosed annually in the UK, 447 000 across Europe and 1.36 million worldwide; of which one third are located in the rectum. Standard primary radical Total Mesorectal Excision (TME) surgery is an oncologically effective treatment for early stage rectal cancer. However, resection of a low rectal tumour requires a permanent stoma in approximately 10% of cases while many more patients have a temporary stoma, some of which are not reversed. Radical surgery, which evolved to treat locally advanced, symptomatic tumours, may not be the optimal method of treatment for early screen-detected tumours and an organ preserving strategy may generate significantly less morbidity without substantially compromising oncological outcomes. STAR-TREC is a rolling phase II/III study. Phase II aimed to assess the feasibility of a large, multi-centre randomised trial comparing radical surgery versus two contrasting organ saving treatments followed by selective transanal microsurgery. Phase III will evaluate two contrasting organ preservation strategies in terms of organ preservation rates, toxicity (clinician and patient-reported) and Health-Related Quality of Life (HRQoL).

NCT ID: NCT02942459 Recruiting - Schizophrenia Clinical Trials

Music Therapy Towards Schizophrenia, Negative Symptoms

Start date: September 1, 2015
Phase: N/A
Study type: Interventional

The Aim of this National study is to examine whether music therapy can reduce negative symptoms and raise Quality of Life for patients suffering from Schizophrenia. It is an Randomized Controlled Trial (RCT), double-blinded study with two arms. 120 Participants are anticipated. The two Arms consist of 25 weekly hours of Music Therapy by educated Music Therapists and time compensated Music Listening by unknown Care Staff Members. The Study is a close Cooperation between Aalborg University (The Music Therapy Research Clinic) and Aalborg University Hospital, Psychiatry.

NCT ID: NCT02940184 Recruiting - Physiology Clinical Trials

GLP-1 Signaling in Truncally Vagotomized Subjects

Start date: June 2016
Phase: N/A
Study type: Interventional

Investigation of the importance of vagal signaling for the glucohomeostatic effects of GLP-1. The study will include physiological studies of truncally vagotomized participants and matched controls.

NCT ID: NCT02931513 Recruiting - Clinical trials for Primary Biliary Cirrhosis

sCD163 in PBC Patients - Assessment of Treatment Response

Start date: September 2016
Phase:
Study type: Observational

Primary biliary cholangitis (PBC) is an autoimmune chronic liver disease, characterised by destruction of the small intrahepatic bile ducts. Ursodeoxycholic acid (UDCA) is the first line treatment for patients with PBC. However, up to 40% of patients respond inadequate to this treatment. sCD163 is a macrophage activation marker shedded into plasma by macrophages in the liver. sMR is a soluble mannose receptor. The investigators want to investigate whether sCD163 and sMR can predict response to treatment with UDCA in newly diagnosed patients with PBC.

NCT ID: NCT02928328 Recruiting - Pain Clinical Trials

Assessment of Peripheral GABA Receptors for Local Pain Relief

Start date: October 2016
Phase: N/A
Study type: Interventional

The effect of peripheral GABAA receptor activation on pain and sensitivity in healthy human subjects has never been investigated. However, as earlier studies suggest that activation of peripheral GABAA receptors is anti-nociceptive in rats, it is important to determine if these findings can be translated into human subjects to determine if peripheral GABAA receptors are a viable target for future analgesic drug development.